Back to Results
First PageMeta Content
Clinical medicine / Medicine / Lung cancer / Biology / KRAS / Non-small-cell lung carcinoma / Biomarker / Ras subfamily / FASN / Fatty acid synthase


FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M
Add to Reading List

Document Date: 2016-04-19 06:39:33


Open Document

File Size: 997,69 KB

Share Result on Facebook
UPDATE